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Abstract
Background: Insulin glargine (LantusH) is a long-acting basal insulin analog that demonstrates effective day-long glycemic
control and a lower incidence of hypoglycemia than NPH insulin. After subcutaneous injection insulin glargine is partly
converted into the two main metabolites M1 ([Gly
A21]insulin) and M2 ([Gly
A21,des-Thr
B30]insulin). The aim of this study was
to characterize the glargine metabolites in vitro with regard to their insulin receptor (IR) and IGF-1 receptor (IGF1R) binding
and signaling properties as well as their metabolic and mitogenic activities.
Methods: The affinity of human insulin, insulin glargine and its metabolites to the IR isoforms A and B or IGF1R was
analyzed in a competitive binding assay using SPA technology. Receptor autophosphorylation activities were studied via In-
Cell Western in CHO and MEF cells overexpressing human IR-A and IR-B or IGF1R, respectively. The metabolic response of
the insulins was studied as stimulation of lipid synthesis using primary rat adipocytes. Thymidine incorporation in Saos-2
cells was used to characterize the mitogenic activity.
Conclusions: The binding of insulin glargine and its metabolites M1 and M2 to the IR were similar and correlated well with
their corresponding autophosphorylation and metabolic activities in vitro. No differences were found towards the two IR
isoforms A or B. Insulin glargine showed a higher affinity for IGF1R than insulin, resulting in a lower EC50 value for
autophosphorylation of the receptor and a more potent stimulation of thymidine incorporation in Saos-2 cells. In contrast,
the metabolites M1 and M2 were significantly less active in binding to and activation of the IGF1R and their mitogenicity in
Saos-2 cells was equal to human insulin. These findings strongly support the idea that insulin glargine metabolites
contribute with the same potency as insulin glargine to blood glucose control but lead to significantly reduced growth-
promoting activity.
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Introduction
Insulin glargine (LantusH, [Gly
A21,Arg
B31,Arg
B32]insulin) is a long-
acting human insulin analog with an almost peakless activity profile
very closely mimicking the natural physiological profile of basal
endogenous insulin secretion [1,1–5]. Insulin glargine differs from
human insulin by substitution of asparagine by glycine in position 21
of the A chain and by carboxy-terminal extension of the B-chain by
two arginine residues. These alterations cause a shift in the isoelectric
pointfrompH 5.4to 6.7. Followingsubcutaneous administrationas a
clear solution of pH 4, insulin glargine precipitates at the injection site
because of its low solubility at physiological pH. The prolonged blood
glucose lowering activity of insulin glargine may be a consequence of
the subsequent slow dissolution of the microprecipitate on the basis of
a low dissociation rate [6]. However, the extended action profile of
insulin glargine may be dependent on more than just a shift in its
isoelectric point [7,8].
Insulin glargine may be released from the microprecipitate by
proteolytic degradation leading to soluble yet fully metabolically
active metabolites. In vivo metabolism studies in rats and dogs have
demonstrated significant plasma levels of two main metabolites of
insulin glargine, M1 ([Gly
A21]insulin) and M2 ([Gly
A21,des-
Thr
B30]insulin), formed by the sequential removal of the two
arginines from the carboxy-terminus of the B-chain and additional
deamination of the threonine in position B30. The intermediate
IM ([Gly
A21,Arg
B31]insulin) can be detected as minor species only
(Fig. 1) [9]. This pattern of insulin glargine metabolism was also
observed following its subcutaneous administration in healthy
humans [10]. Interestingly, degradation to both M1 and M2
occurred at the site of injection and continued within the
circulatory system, although with considerable variation in efficacy
and time course between the individuals tested. Analysis of tissue
samples from the site of injection revealed an average ratio of
50:50 for parent compound and M1/M2 [10]. In vitro incubation
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metabolizing of insulin glargine into M1 from 46% to 98% [11].
The processing enzymes have not been identified so far, but
metallocarboxypeptidases such as carboxypeptidases E, H, N and
U represent candidates for the rapid and efficient metabolism of
insulin glargine [11]. These enzymes are found in plasma and are
likely to occur also in subcutaneous tissues [11].
The efficient generation of IM, M1, and M2 at the
subcutaneous injection site and in plasma carries the notion that
the proteolytic degradation products of insulin glargine contribute
to the long-lasting systemic metabolic activity at least in part. In
addition, it may shed new light on the current intense and
controversial debate concerning the growth-promoting activity of
human insulin and insulin analogs as determined in vitro [12–15]
and its in vivo relevance for insulin therapy [16–18]. The growth-
promoting effects of human insulin or insulin analogs are usually
studied in cell lines under in vitro experimental conditions in the
absence of IGF’s and other physiological serum growth factors.
However, several such studies have yielded conflicting results that
may be due to experiment-to-experiment variability in specific cell
lines and/or to the precise experimental conditions used [18,19].
In addition, modification of human insulin by amino acid
substitutions is known to change the signaling properties of the
hormone. One prominent example is the aspartate modification in
the B-chain of insulin, Asp
B10, resulting in a higher affinity towards
both IR and IGF1R and a prolonged occupancy time for the IR
[12]. The fact that [Asp
B10]insulin has induced a higher incidence
of breast cancer in a 1-year toxicity study in Sprague-Dawley rats
[20] and a higher proliferation rate of the osteosarcoma cell line
Saos-2 [12] has led to the contention that insulins with a profile in
vitro similar to [Asp
B10]insulin might also have a potential tumor-
promoting activity.
The human insulin receptor is expressed as two isoforms as a
result of alternative splicing. The two mature proteins IR-A (short
form) and IR-B (long form) differ by the presence or absence of 12
amino acids encoded by exon 11 at the carboxy-terminus of the
extracellular a-subunit, downstream of the carboxy-terminal
sequence that is essential for ligand binding [21,22]. IR-A appears
to be expressed predominantly in fetal tissues and cancer, whereas
IR-B is expressed in normal adult tissues [23]. Importantly, there
is considerable evidence that IR-A, which has the peculiar
characteristic to bind not only insulin but also IGF-2, may play
a critical role in the development of breast cancer [24], thyroid
cancer [25] and leiomyosarcoma [26]. In addition, a role of the
isoform IR-A has been discussed for hybrid receptors, as increased
expression of IR-A/IGF1R hybrids has been found in tumors
[27].
Therefore it is important to determine the metabolic and
mitogenic as well as receptor binding activities of insulin glargine
metabolites, which so far have only been reported in part for M1
[12]. In the present study we provide IR- and IGF1R-mediated
metabolic and mitogenic signaling profiles for insulin glargine, IM,
M1, and M2, including the differentiation between IR-A and IR-B.
Materials and Methods
Materials
Human insulin, insulin glargine, insulin glargine intermediate
IM ([Gly
A21,Arg
B31]insulin), M1 ([Gly
A21]insulin), M2
([Gly
A21,des-Thr
B30]insulin), and [Asp
B10]insulin were produced
by recombinant DNA techniques or enzymatic semisynthesis and
purified to homogeneity and were made available by Process
Development Biotechnology (Sanofi-Aventis, Frankfurt, Ger-
many). Human A14[
125I]-insulin was prepared by the radio-
synthesis group of Sanofi-Aventis (Frankfurt, Germany) [28].
[2-
14C]-thymidine was obtained from Perkin Elmer (Boston, MA,
USA). IGF-1 and IGF-2 were obtained from R&D Systems
(Wiesbaden-Nordenstadt, Germany) and from Cell Sciences
(Canton, MA, USA). Complete Protease Inhibitor was from
Roche (Penzberg, Germany). SPA PVT PEI treated WGA Beads
were purchased from GE Healthcare (Amersham, UK). Cell
culture reagents and antibodies were obtained from the suppliers
as indicated in the methods section. All other chemicals were of
reagent grade.
Receptor Binding Assays
The binding of the different insulins to the human IR-A and IR-
B was analyzed in a competitive binding assay using the
scintillation proximity assay as previously described [29,30].
Plasma membranes were enriched from CHO cells overexpressing
either IR-A or IR-B (,1.3610
5 IR-A per cell and ,2.2610
5 IR-B
per cell as determined by FACS analysis, unpublished data) by a
series of differential centrifugations including a single flotation
through a one-step sucrose gradient. Briefly, cells were grown to
confluence and gently detached, transferred to a centrifugation
tube followed by centrifugation for 10 minutes at 6006ga t4 uC.
The pellet was resuspended in ice-cold 2.25 STM buffer
(2.25 mol/L sucrose, 5 mmol/L Tris-HCl pH 7.4, 5 mmol/L
MgCl2, 1x Complete Protease Inhibitor) and disrupted using a
hand-held Dounce homogenizer followed by sonication. This
homogenate was transferred to a centrifugation tube, overlaid with
0.8 STM buffer (0.8 mol/L sucrose, 5 mmol/L Tris-HCl pH 7.4,
5 mmol/L MgCl2, 1x Complete Protease Inhibitor) and centri-
fuged for 90 minutes at 100 0006ga t4 uC. The emerging pellicle
at the interface was collected, transferred to a new tube and
washed two times with PBS by centrifugation for 10 minutes at
15006g. The final pellet was resuspended in a small volume of
dilution buffer (50 mmol/L Tris-HCl pH 7.4, 5 mmol/L MgCl2,
1x Complete Protease Inhibitor) and homogenized with a Dounce
homogenizer. These plasma membrane preparations were stored
until usage at –80uC.
Binding experiments were conducted in 96-well microplates.
Per well 2 mg of membranes were incubated with 0.25 mg wheat
 
 
Figure 1. Insulin glargine metabolites. The long-acting insulin
glargine (LantusH, [Gly
A21,Arg
B31,Arg
B32]insulin) is metabolized in vivo in
subcutaneous tissue and in bloodstream of healthy humans by
sequential cleavage of the C-terminus of the B chain. Two primary
degradation products M1 and M2 have been reported, which are both
structural similar to human insulin [10]. Besides M1 and M2 an
intermediate IM was also identified but only in minor quantities.
doi:10.1371/journal.pone.0009540.g001
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100 pmol/L A14[
125I]-insulin and various concentrations of
unlabeled insulins in a binding buffer containing 0.05 mol/L
Tris-HCl pH 7.8, 0.15 mol/L NaCl, 0.1% BSA, Complete
Protease Inhibitor for 12 hours at room temperature (23uC).
The radioactivity was measured at equilibrium in a microplate
scintillation counter (Wallac Microbeta, Freiburg, Germany).
Receptor Autophosphorylation Assays
CHO cells expressing either the IR-A or the IR-B isoform were
used for IR autophosphorylation assays using In-Cell Western
[31]. For the analysis of IGF1R autophosphorylation the receptor
was overexpressed in a mouse embryo fibroblast 3T3 Tet off cell
line (BD Bioscience, Heidelberg, Germany) that was stably
transfected with IGF1R tetracycline-regulatable expression plas-
mid resulting in the expression of ,2.6610
5 IGF1R per cell (as
determined by FACS analysis, unpublished data). In order to
determine the receptor tyrosine phosphorylation level, cells were
seeded into 96-well plates and grown for 48 h. Cells were serum
starved with serum-free medium aMEM (PAN Biotech GmbH,
Aidenbach, Germany) for 3–4 h. The cells were subsequently
treated with increasing concentrations of either human insulin,
IGF-1, IGF-2 or the indicated insulin analog for 15 min at 37uC.
After incubation the medium was discarded and the cells were
fixed in 3.75% freshly prepared para-formaldehyde for 20 min.
Cells were permeabilized with 0.1% Triton-X-100 in PBS for
20 min. Blocking was performed with Odyssey blocking buffer (LI-
COR, Bad Homburg, Germany) overnight at 4uC. Anti-pTyr
4G10 (Millipore, Schwalbach, Germany) was incubated for 2 h at
room temperature. After incubation of the primary antibody, cells
were washed with PBS+0.1% Tween20. The secondary anti-
mouse-IgG-800-CW antibody (Rockland, Gilbertsville, PA, USA)
was incubated for 1 h. Results were normalized by the
quantification of DNA with TO-PRO3 dye (Invitrogen, Karls-
ruhe, Germany). Data were obtained as relative units (RU) and are
presented as fold over basal.
Metabolic Activity Assay
The metabolic activity of the different insulins was compared
using insulin-stimulated lipid synthesis in primary rat adipocytes.
Primary rat adipocytes were prepared according to published
procedures [32,33]. Briefly, rats (Sprague-Dawley, male, 140–
160 g, fed ad libitum) were provided from Charles-River (Sulzfeld,
Germany) and killed by cervical dislocation in accordance with the
German animal protection law. The animals were used for the
preparation of primary adipocytes, exclusively, and were not
subjected to any pretreatment, such as drug administration or
starvation. Epididymal fat pads were rapidly removed, stripped of
blood vessels and placed in PBS. Subsequently, the pads were
washed with KRBB bubbled with 5% O2/95% CO2. Each pad
was then cut into two or three pieces. Two pieces of each were
incubated with 1.5 mL of digestion buffer (10 mg collagenase
[Worthington Inc., CLS, type I, 190 units/mg] in 10 ml of KRBB
containing 9 mg glucose) for 15–30 min at 37uC in a shaking
water bath (240 cycles/min). Released adipocytes were separated
from residual undigested tissue by passage through a nylon web
(mesh size 150 mm) and washed by flotation in a plastic tube two
or three times with KRBB and adjusted to the appropriate titer of
3.5610
5 cells/mL. For distribution of the adipocytes, 200 mLo f
the suspension was removed under continuous gentle stirring with
a plastic agitator.
Lipid synthesis was measured as the incorporation of [3-
3H]glu-
cose into toluene-extractable lipids, at a final cell titer of
0.7610
4 cells/mL in KRBB (1.2 mM KH2PO4, 1.2 mM MgSO4,
4.8 mM KCl, 25 mM NaHCO3, 120 mM NaCl, 2.4 mM CaCl2,
containing 1% BSA [defatted, fraction V, Sigma, Deisenhofen,
Germany] and 37 mM glucose and adjusted to pH 7.4) according
to published procedures (Mu ¨ller et al., 2008) with the following
modifications: 680 mL of KRBB were filled into 10-mL scintilla-
tion vials and supplemented with 100 mL of D-[3-
3H]glucose
(2 mCi/mL KRBB, 1 mM, Amersham-Buchler, Braunschweig,
Germany) and 20 mL of insulin solution in KRBB. Lipid synthesis
was started by the addition of 200 mL of adipocyte suspension in
KRBB. After incubation for 90 min at 37uC under an atmosphere
of 5% O2/95% CO2 and gentle shaking, 10 mL of toluene-based
scintillation cocktail (Quickszint 501, Zinsser, Germany) was
added. The samples were vigorously mixed and after phase
separation (2 to 4 h) measured for radioactivity by liquid
scintillation counting. Determination of the radioactivity con-
tained in the toluene phase and corrected for non-specific spill-
over of the radioactivity of unincorporated radiolabelled glucose
contained in the water phase predominantly reflects the de novo
lipid synthesis.
Mitogenic Potency
The human osteosarcoma cell line Saos-2 was obtained in
frozen aliquots from the European Collection of Cell Cultures
(ECACC, Salesbury, UK). Cells were grown in McCoy’s 5a
medium (Gibco, Grand Island, NY, USA) supplemented with 10%
fetal calf serum (PAN Biotech GmbH, Aidenbach, Germany) and
2 mM (final) L-glutamine (Sigma Aldrich, Irvine, UK). Subcon-
fluent cultures (9-15610
6 cells per 225 cm
2 flask) were used to
determine the mitogenic activity of the test compounds.
For measuring thymidine incorporation 40,000 cells were
seeded per well of a 96-well Cytostar-T scintillation microplate
(GE Healthcare, Amersham, UK) and the plates were incubated
overnight at 37uC in a humidified atmosphere containing 5%
CO2. The serum-containing medium was removed and replaced
by 200 mL serum-free McCoy’s 5a medium supplemented with
0.5% (w/v) BSA (Gibco, Grand Island, NY, USA), 2 mM L-
glutamine and antibiotics (penicillin 100 units, streptomycin 100
units, amphotericin B 0.25 mg/mL final, Gibco, Grand Island,
NY, USA). The plates were incubated for 4 hours at 37uCi na
humidified atmosphere containing 5% CO2. 150 mL of the
medium were removed and substituted by 150 mL of serum-free
medium containing the different insulins or IGF-1 (Cell Sciences,
Canton, MA, USA) at the indicated concentrations and the plates
were incubated at 37uC in a humidified atmosphere containing
5% CO2. After 19 hours 10 mL of [2-
14C]-thymidine solution
(.50 mmol/L, 3.7 MBq/mL) diluted in serum-free McCoy’s 5a
medium were added per well to yield a final concentration of
500 nCi/mL and the plates were incubated for 6 hours at 37uCi n
a humidified atmosphere containing 5% CO2.
14C-thymidine
incorporation was measured in a Wallac 1450 Micro Beta Trilux
Scintillation counter. Dose-response curves were obtained by
testing ten different concentrations of the ligands with every
concentration tested by octuplicate samples.
Statistic Analysis
For each experiment, IC50 or EC50 values were obtained using
the 4-parameter logistic model according to Ratkowsky and Reedy
(1986). The adjustment was obtained by non-linear regression
using the Levenberg-Marquardt algorithm in SAS v9.1.3 software
via Biost@t-Speed V2.0-LTS internal application. If necessary,
lower and upper asymptotes were set to 0 and 100, respectively.
Statistical analysis was performed with one-way analysis of
variance (ANOVA), followed by a Bonferroni comparison or data
Glargine Metabolites
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(San Diego, CA, USA).
Results and Discussion
Metabolic Signaling and Activity of Insulin Glargine and
Its Metabolites IM, M1, and M2
Previous studies have shown that insulin analogs differ only in
potency but produce identical maximal responses. Accordingly, a
good correlation between the potency in insulin receptor binding,
induction of autophosphorylation and stimulation of lipid synthesis
has been observed for insulin analogs [34]. Relative to human
insulin, insulin glargine and its metabolite M1 demonstrated a
reduced insulin receptor binding of 86% and 78%, respectively,
and decreased lipid synthesis of 60% and 88%, respectively [12].
First, we analyzed the binding characteristics of insulin glargine
and its metabolites M1, M2, and IM to IR-A and IR-B. Using
plasma membranes from CHO cells that overexpress the receptor
isoforms, the IC50 value for competition of unlabeled ligand with a
constant concentration of radioactively labeled human insulin
were determined as a measure of affinity. The results are shown in
Table 1 with representative competition curves given in Figure 2 A
and B. Both IR isoforms bound human insulin with high affinity
that did not significantly (p=0.23) differ between IR-A
(IC50=0.49 nmol/L) and IR-B (IC50=0.57 nmol/L). In contrast,
IR-A displayed a considerably higher affinity for IGF-1 (2.7-fold)
and IGF-2 (7.5-fold) than IR-B, but the affinity of IR-A and IR-B
for IGF-1 were approximately 130- and 300-fold, respectively, less
potent than those for human insulin. Both isoforms bound IGF-2
with higher affinity than IGF-1 but with lower affinity than human
insulin. These data are consistent with results published previously
[35–39] and demonstrated the validity of our experimental system.
Insulin glargine and its metabolites IM, M1, and M2 showed no
difference in their respective binding affinities to the two IR
isoforms and were only 40–50% less active than human insulin. In
contrast, [Asp
B10]insulin showed significant isoform selectivity,
being 3.5-fold more active towards IR-A (p,0.01), and was 8.2-
and 2.7-fold more potent in binding to IR-A and IR-B,
respectively, relative to human insulin.
Insulin receptor autophosphorylation was studied using CHO cells
overexpressing either IR-A or IR-B. For detection an immunocyto-
chemical microplate assay (In-Cell Western) based on two-colour
fluorescence was applied [31]. The observed EC50 values for
stimulation of autophosphorylation of the IR isoforms with human
insulin, insulin glargine, its metabolites IM, M1 and M2 and IGF-1
and IGF-2 correlated well with their binding affinities to the
corresponding receptors (Tab. 1, Fig. 2 C and D). For human insulin,
insulin glargine and its metabolites the EC50 values were comparable
for IR-A and IR-B with insulin glargine and its metabolites exhibiting a
30–50% decrease in activity towards both isoforms relative to human
insulin. IGF-1 and more potently IGF-2 were capable in stimulating
the autophosphorylation of IR-A. In contrast, stimulation of IR-B
autophosphorylation was less pronounced with IGF-1 (EC50 value
.400 nmol/L) and IGF-2 (EC50 value=384668 nmol/L). The most
potent stimulant for both IR-A and IR-B autophosphorylation was
[Asp
B10]insulin with comparable EC50 values, which did not reflect the
differences observed in the IR isoform affinities [12].
For determination of the metabolic activity primary rat
adipocytes were used that possess a high insulin sensitivity and
responsiveness. They reflect the physiological situation of insulin
target cells with regard to signal transduction processes and
regulation of glucose and lipid metabolism (e.g. glucose uptake and
esterification into lipids) more closely than cultured muscle cells
and adipocyte cell lines. mRNA expression of IR-B is significantly
higher than that of IR-A in rat epididymal white adipose tissue
from which primary adipocytes are derived [23]. By using fully
differentiated and maximally insulin-sensitive adipocytes from
young rats, any difference in metabolic activity between human
insulin, insulin glargine and glargine metabolites is due to
differential interaction with the IR-B rather than the IR-A.
Assaying lipid synthesis with primary rat adipocytes for the
measurement of metabolic activity is based on the incorporation of
radiolabelled glucose into total lipids. This pathway is under the
strict control of insulin at the low glucose concentrations used.
As expected on the basis of previously reported data on the
stimulation of lipid synthesis in rat adipocytes [12], [Asp
B10]insulin
and IGF-1 exerted the highest and lowest metabolic activities,
respectively, among all proteins tested, with EC50 value of 0.2-fold
lower and 422-fold higher, respectively, relative to insulin.
Furthermore, insulin glargine and M1 were reported to exhibit
60% and 88%, respectively, of the metabolic activity of human
insulin [12]. These findings were confirmed in the present study as
reflected in the considerable right-ward shifts of the concentration-
response curves for insulin glargine and M1 vs. human insulin
Table 1. Summarized in vitro data for insulin and glargine metabolites.
Analog
IR-A
affinity
IR-B
affinity
IR-A auto-
phosphorylation
IR-B auto-
phosphorylation
Metabolic
potency IGF1R affinity
IGF1R auto-
phosphorylation
Mitogenic
potency
IC50 IC50 EC50 EC50 EC50 IC50 EC50 EC50
(nmol/L) (nmol/L) (nmol/L) (nmol/L) (nmol/L) (nmol/L) (nmol/L) (nmol/L)
Human insulin 0.4960.04 0.5760.02 11.061.3 11.761.4 0.04560.003 289653.3 447638.7 12.2560.27
Glargine 0.8360.08 1.1060.12 18.462.4 23.662.1 0.06660.005 63.2619.9 87.5610 1.6160.26
Glargine IM 0.7860.03 1.0860.06 23.162.7 20.961.3 0.09860.012 80.0610.2 179619.6 3.7560.31
Glargine M1 1.0260.03 1.3560.20 18.662.5 18.161.7 0.13960.009 649631.9 644656.9 16.2562.35
Glargine M2 0.9360.16 1.0960.06 19.261.6 21.462.3 0.08760.007 427620.6 485643.6 17.9066.50
[Asp
B10]insulin 0.0660.01 0.2160.03 5.160.7 3.3260.78 0.03160.005 104612.8 72.767.6 1.5260.15
IGF-1 64.565.1 171650 449661.7 .1,000 19.0160.93 0.8960.19 2.960.4 0.2260.05
IGF-2 6.260.34 46.667.8 85.465.5 384668.4 - 6.6862.24 - -
Data are means 6 SEM. All analogs were tested at least three times on different days. Activity was determined within each experiment and then averaged to yield a
single reported mean value. IM – intermediate ([Gly
A21,Arg
B31]insulin), M1 – metabolite 1 ([Gly
A21]insulin), M2 – metabolite 2 ([Gly
A21,des-Thr
B30]insulin).
doi:10.1371/journal.pone.0009540.t001
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(Tab. 1, Fig. 3). The glargine metabolites M2 and IM, here
investigated for biological activity for the first time, were also less
active (1.2- and 1.4-fold) than insulin glargine but more active than
M1 (0.6-fold lower EC50 values). The maximal responses in
stimulating lipid synthesis are the same for human insulin, insulin
glargine and its metabolites M1, M2 and IM (15- to 20-fold above
basal, depending on the batch of adipocytes used).
The relative metabolic activities of human insulin . insulin
glargine = glargine metabolites correlate well with their binding
affinities and autophosphorylation of IR-A and IR-B. This is
compatible with previous studies demonstrating that ligand affinity
and activation (i.e. autophosphorylation) of the IR are the key
events for initiation of downstream signaling to the metabolic
effector systems of insulin and its analogs [6,40].
The maintenance of binding, autophosphorylation and meta-
bolic activities of insulin analogs with modified carboxy-terminus
confirm the previous findings that amino acid modifications at the
insulin B-chain beyond position B25, in particular the B26-B30
region, do not play a critical role in its recognition by both
isoforms of the IR [41,42] and thus in metabolic signaling in
insulin target cells [6,43]. The slightly lower binding, autopho-
sphorylation and metabolic activities of M1 relative to those of
human insulin are in agreement with the previous suggestion that
the minor structural change caused by loss of the salt bridge
between Asn
A21 and Arg
B22 leads to a (small) reduction in IR
affinity [44]. In consequence, the slight reduction in metabolic
activity of insulin glargine vs. human insulin derives predominantly
from altered structural features at the carboxy-terminus of the B-
chain and rather than from the amino acid substitution at A21.
Taken together, the present data clearly demonstrate that the
major metabolites of insulin glargine detected in rats, dogs, and
humans [9,10] are metabolically active. Since a ratio of 50:50 for
parent compound and M1/M2 was reported in tissue samples
derived from the site of injection in humans [10] and in vitro
metabolism of insulin glargine resulted into 46% to 98% appearance
of M1 [11], it is reasonable to assume that the metabolites of insulin
glargine will contribute to the blood glucose lowering profileobserved
after administration of insulin glargine, dependent on the extent of
their generation at the subcutaneous injection site and in plasma in
the course of carboxypeptidase action [11].
Mitogenic Signaling and Activity of Insulin Glargine and
Its Metabolites IM, M1, and M2
Although the predominant physiological function of insulin is
the regulation of glucose and lipid metabolism via the insulin
 
 
Figure 2. Binding and signaling of insulin glargine and its metabolites to the human insulin receptor isoform A and B. Binding of the
insulin analogs to the human IR-A (A) or IR-B (B) was analyzed in a competitive binding assay using SPA technology. The binding of a constant
concentration of [
125I]insulin to plasma membranes from CHO cells overexpressing either IR-A or IR-B was measured in presence of increasing
concentrations of unlabeled competing ligand after incubation at room temperature for 12 h. All data has been corrected for non-specific binding
and are expressed as percentage of [
125I]insulin in absence of competing ligand. To analyze the insulin-stimulated activation and subsequent
autophosphorylation of the insulin receptor CHO cells overexpressing the human IR-A (C) or IR-B (D) were stimulated for 15 min at 37uC with
increasing concentrations of peptides, then the cells were fixed with 3.7% PFA and the amount of phosphotyrosines was analyzed via In-Cell Western.
The data represent mean values 6 SEM of at least 3 individual experiments measured in quadruplicate.
doi:10.1371/journal.pone.0009540.g002
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different tissues and primary cell lines as well as in tumors and
tumor-derived cell lines through either IR or IGF1R signaling
pathways [34].
Insulin glargine resembles [Asp
B10]insulin in increasing the
incorporation of radiolabelled thymidine into DNA in Saos-2 cells
with comparable EC50 values, which are 7- to 10-fold lower than
those for human insulin (Tab. 1, Fig. 4 C). In addition, the
affinities for IGF1R and the EC50 values for IGF1R autopho-
sphorylation of insulin glargine and [Asp
B10]insulin were compa-
rable and moderately greater, respectively (Tab. 1, Fig. 4 A and B).
Relative to human insulin, insulin glargine and [Asp
B10]insulin
were about 5-fold more potent in the stimulation of IGF1R
autophosphorylation. Relative to IGF-1, human insulin, insulin
glargine and [Asp
B10]insulin were about 150, 30 and 25 times less
potent. These findings are in agreement with the observations
described by Kurtzhals et al. [12] and Seipke et al. [45]; the latter
have been intensively evaluated by European Medical Evaluation
Agency during the approval of insulin glargine for marketing
authorization [46]. This may be explained by involvement of the
carboxy-terminal part of the insulin B-chain in interaction with the
IGF1R, as amino acid substitutions at positions B28-B32, in
particular, the number and position of basic residues, have been
shown to affect the binding affinity to the IGF1R [47].
Consequently the two major metabolites M1 and M2 were
significantly less mitogenic than glargine and comparable to
normal insulin. The sequential removal of the amino acids from
the carboxy-terminus of the B-chain led to a decreased affinity
towards IGF1R and thus resulted in higher EC50 values for
IGF1R autophosphorylation (Tab. 1, Fig. 4 A and B). The
intermediate IM, in which only Arg
B32 is missing, had a 2-fold
higher potency relative to human insulin. However, for M1 and
M2, the IGF1R affinity was significantly reduced and EC50 values
for IGF1R autophosphorylation were .400 nmol/L. The mito-
genic potencies of IM, M1 and M2 were reduced relative to insulin
glargine, with an activity of M1 and M2 as low as human insulin
(Tab. 1, Fig. 4 C).
A correlation between IGF1R autophosphorylation and cell
proliferation has been recently assumed by Shukla et al. [15], who
observed an enhanced growth of the malignant cell line MCF7
after insulin glargine stimulation. The authors have observed 10%
and 50% increases of cellular proliferation at 0.31 and about
15 nmol/L. This effect seemed to be linked to activation of the
IGF1R and the MAPK pathway, since siRNA knockdown of
IGF1R decreased the response [15]. Unfortunately, no dose-
response curve of IGF1R autophosphorylation as well as no
proliferation data from siRNA knockdown of IR have been
presented so far. Other breast cancer cell lines containing IR and
IGF1R did not respond to human insulin (BT474, T47D, ZR75-1,
MDA-MB231, HCC1937). Furthermore, with the benign cell line
MCF10 human insulin and insulin glargine did not show any
difference [15]. Several studies have been dedicated to the growth
response of MCF7 and other tumor cell lines towards insulin and
insulin analogs. Staiger et al. [14] found no evidence for an
increased mitogenic activity of insulin glargine relative to human
insulin. Liefvendahl et al. [48] tested insulin glargine on MCF-7
and SKBR-3 cells and found a slightly increased mitogenic activity
of insulin glargine without statistical significance. Weinstein et al.
[49] tested the potency of insulin, insulin glargine and the two
insulin analogs insulin detemir and insulin lispro in MCF-7 cells,
HCT-116 (colorectal cancer) and PC-3 (prostate cancer) cells and
showed an increased mitogenic potency of insulin glargine and
insulin detemir.
These data are likely to support an involvement of the IGF1R
signaling cascade but are not yet conclusive. Consequently it is
hard to draw any conclusion from these in vitro results for the role
of an insulin-mediated IGF1R-promoted cell growth in vivo.
Linking mere IGF1R activation by insulin glargine and by
[Asp
B10]insulin in vitro and tumor-promoting activity in vivo ignores
the fact that the IR activity profile of both molecules differ
completely. Whereas [Asp
B10]insulin has a high affinity for both
receptor isoforms IR-A and IR-B resulting in a decreased EC50
value for receptor autophosphorylation and in a prolonged
occupancy leading to increased mitogenicity [50], insulin glargine
is less active on both IR-A and IR-B relative to human insulin and
has a dissociation rate similar to that of human insulin [12,51].
Taken together, this raises the possibility that the higher tumor
incidence found in rats in the course of [Asp
B10]insulin treatment
is predominantly mediated by the IR signaling axis involving both
IR-A and IR-B (Tab. 1). Most important the data presented
Figure 3. Metabolic activity of insulin glargine and its metabolites in rat adipocytes. To compare the metabolic activity of glargine and its
metabolites insulin-stimulated lipid synthesis in isolated primary rat adipocytes was analyzed by incorporation of [3-
3H]glucose into toluene-
extractable lipids and subsequent measurement of radioactivity by liquid scintillation counting. The adipocytes were treated with increasing
concentrations of insulin, analogs, metabolites or IGF-1 for 90 min at 37uC in the presence of [3-
3H]glucose. Each point represents the mean 6 SEM of
five different adipocyte preparations with activity measurements done in duplicate.
doi:10.1371/journal.pone.0009540.g003
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activity higher than human insulin can be excluded for the IR-
mediated pathway.
Importantly, healthy subjects and patients with type 1 diabetes
who received insulin glargine injections showed free serum insulin
glargine levels between 70 to 90 pmol/L with peak levels of about
,200 pmol/L after injection [52–55]. The therapeutic insulin
glargine concentrationsreported so farare80-to 200-fold below the
total plasma concentrations of IGF-1. Notably, up to 99% of the
circulating IGF-1 is bound to the IGF-binding proteins 1–6 in
human plasma [13,56]. Therefore, the concentration of free IGF-1
may be within the range of the plasma concentration of insulin
glargine. However, despite the putative comparable plasma
concentrations the ,100-fold reduced affinity of insulin glargine
towards IGF1R compared to that of IGF-1 makes a competition
even of non-metabolized insulin glargine with endogenous IGF-1 at
the receptor unlikely. Furthermore, the concentration of free IGF-1
may be elevated during certain diseases and metabolic states, which
are known to considerably reduce the expression of IGF-binding
proteins [57,58] making interaction of insulin glargine with the
IGF1R in course of displacement of IGF-1 even less likely.
Insulin glargine has been evaluated extensively in a 2-year life-
time carcinogenicity study in rats without evidence of tumor-
promoting activity greater than human insulin [59]. In these
studies plasma insulin concentrations were 15 to 25 nmol/L,
covering parent compound and active metabolites. In conse-
quence, actual glargine concentrations may be overestimated, the
extent of which depends on the degree of proteolytic degradation
at both the injection site and the serum. Quantitative assessment of
the insulin glargine metabolism in humans is evolving, and will
bring further clarification.
Conclusion
The present data unequivocally demonstrate similar metabolic
signaling in vitro and activity in rat adipocytes of insulin glargine
and its major metabolites with comparable engagement of IR-A
and IR-B. In contrast, the insulin glargine metabolites were found
to be less potent in mitogenic signaling and less active in Saos-2
proliferation assay compared to insulin glargine. The formation of
insulin glargine metabolites may help to explain the established
efficacy and safety of insulin glargine as observed in clinical
practice and particularly in long-term clinical trials.
Figure 4. Activity of insulin analogs on the human IGF1R and mitogenic potential in Saos-2 cells. Analysis of binding to the human IGF1R
using [
125I]IGF-1 as radioactive ligand (A) and analysis of the insulin-stimulated autophosphorylation of the human IGF1R overexpressed in MEF cells
(B) were done as described in figure 2 and Materials and Methods. Data are given as means 6 SEM. (C) To compare the mitogenic potential of the
insulin analogs with that of human insulin, DNA synthesis was determined by [
14C]thymidine incorporation in Saos-2 cells cultured in Cytostar-T
scintillation microplates. Confluent cells were starved for 4 h and then incubated for 19 h with increasing concentrations of IGF-1, insulin or analogi n
serum free medium. [
14C]thymidine was added for further 6 h and the radioactivity measured in a Wallac Micro Scintillation counter. Data are given as
means 6 SEM from octuplicate sample.
doi:10.1371/journal.pone.0009540.g004
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